Fastest Ever Robotics-Driven COVID-19 Mass Testing Platform Gives 99% Accurate Results

A new robotics-driven COVID-19 mass testing platform that has been rolled out is up to three times faster than competitors for mass testing and aims to provide affordable, effective and easy-to-access pre-emptive diagnostic solutions for a range of medical conditions that facilitate early intervention and improve overall health outcomes.

Salient Bio (London, UK) has announced the commercial launch of its robotics-driven COVID-19 mass testing platform which facilitates COVID-secure environments at a quicker and more cost effective rate than the closest approved competitor, with a same day results notification process and a very cost effective per unit price for businesses conducting mass testing. The platform is reagent agnostic, meaning that disruption in supply chains can be mitigated by a shift to different reagent suppliers without it calling for wholesale infrastructure change at Salient’s labs, therefore limiting disruption and costs. Its accuracy, fast delivery and cost effectiveness make Salient Bio’s modular diagnostics platform ideal for sectors that require a safe environment for regular human contact, such as logistics, facilities management, education and manufacturing.


“With the rollout of vaccines likely to be staggered, rapid and accurate mass testing will play a vital role in the coming months in our immediate fight against COVID,” said Dr. Miles Priestman, Co-founder of Salient Bio. “Yet existing diagnostic labs often involve error prone manual processes – there is a huge opportunity to reinvent how they operate from the ground up. Using state of the art robotics and bespoke software development we hope to do just this, bringing significant cost and operational efficiency gains to help bring diagnostic labs fully into the 21st century.”

Related Links:
Salient Bio